Date published: 2025-10-11

1-800-457-3801

SCBT Portrait Logo
Seach Input

TESSP2 Inhibitors

Chemical inhibitors of TESSP2 can affect its activity through various mechanisms involving the interruption of signal transduction pathways. Wortmannin and LY294002 are potent inhibitors of the PI3K/AKT pathway, a crucial signaling mechanism that TESSP2 may rely on for proper function. By inhibiting PI3K, these chemicals can prevent the activation of AKT, a kinase that phosphorylates a wide array of substrates, potentially including TESSP2 or its partners. This inhibition effectively halts the propagation of signals necessary for TESSP2's functions, resulting in its functional inhibition. Rapamycin, acting downstream, specifically inhibits the mTOR pathway, which is intricately connected to the PI3K/AKT pathway. The inhibition of mTOR by Rapamycin could disrupt TESSP2's involvement in processes regulated by mTOR, such as protein synthesis and cell proliferation, leading to a decrease in TESSP2's functional activity.

Further targeting different aspects of cellular signaling, PD98059 and U0126 function as MEK inhibitors. These inhibitors block the activation of the MEK/ERK pathway, which TESSP2 might utilize. The prevention of ERK activation by these chemicals means that any roles TESSP2 plays in response to ERK-mediated signals would be suppressed. The p38 MAP kinase is another target, with SB203580 impeding its activity. As p38 MAPK is involved in stress responses and cytokine production, the inhibition of this kinase by SB203580 can lead to a reduction in TESSP2's role in these responses. Similarly, SP600125 inhibits the JNK pathway, a signaling route that can modulate TESSP2's function by altering the phosphorylation state of proteins in the pathway. Src family kinases, targeted by the inhibitor PP2, and broad-spectrum kinase activities, including Src family kinases affected by Dasatinib, are essential for multiple phosphorylation events. Inhibition of these kinases can prevent TESSP2 from achieving its active state. Lastly, Imatinib, Erlotinib, and Sorafenib target specific tyrosine kinases such as ABL, EGFR, and RAF, respectively.

SEE ALSO...

Items 11 to 12 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Erlotinib, Free Base

183321-74-6sc-396113
sc-396113A
sc-396113B
sc-396113C
sc-396113D
500 mg
1 g
5 g
10 g
100 g
$85.00
$132.00
$287.00
$495.00
$3752.00
42
(0)

Erlotinib is an EGFR inhibitor. EGFR is involved in numerous signaling pathways, including those that could involve TESSP2. By inhibiting EGFR, Erlotinib can disrupt the signaling cascades that activate TESSP2, leading to a functional inhibition of this protein.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$56.00
$260.00
$416.00
129
(3)

Sorafenib is a RAF inhibitor that targets multiple kinases involved in the MAPK pathway. Since TESSP2 is implicated in signal transduction, inhibiting RAF kinases can lead to functional inhibition of TESSP2 by preventing the downstream signaling required for its activity.